Skip redundant pieces
Urology Research Laboratory
School of Medicine  :  Department of Urology  :  Urology Research Laboratory

Publications

  • Wanyi Tai, Ravi Shukla, Bin Qin, Li B; Kun Cheng.  Development of a peptide-drug conjugate for prostate cancer therapy.  Molecular Pharmaceutics, accepted, April 2011.
  • Liu J, Youn H, Yang J, Du N, Liu J, Liu H, Li B. G-protein alpha-s and -12 subunits are involved in androgen-stimulated PI3K activation and androgen receptor transactivation in prostate cancer cells. The Prostate, 2011 Feb 9. doi: 10.1002/pros.21345. PMID21308712. (As corresponding author).
  • Zhu Q, Yang J, Han S, Liu J, Holzberlien J, Thrasher JB and Li B. Suppression of GSK-3 activity reduce tumor growth of prostate cancer in vivo. The Prostate, 2010 Oct 28. [Epub ahead of print] PMID: 21031441. (As corresponding author).
  • Li C, Ford ES, Li B, Giles WH, Liu S. Association of testosterone and sex hormone-binding globulin with metabolic syndrome and insulin resistance in men. Diabetes Care. 2010 Jul;33(7):1618-24. PMID: 20368409
  • Gao X, Pang J, Li LY, Liu WP, Di JM, Sun QP, Fang YQ, Liu XP, Pu XY, He D, Li MT, Su ZL, Li B. Expression profiling identifies new function of collapsin response mediator protein 4 as a metastasis-suppressor in prostate cancer. Oncogene. 2010 Jun 14. 29(32):4555-66. [Epub ahead of print] PMID: 20543870
  • Yang J, Takahashi Y, Cheng E, Liu J, Terranova PF, Zhao B, Thrasher JB, Wang HG, Li B. GSK-3{beta} promotes cell survival by modulating Bif-1-dependent autophagy and cell death. J Cell Sci. 2010 Feb 16. 123(6)861-870. (As corresponding author).
  • Sun A, Tang J, Terranova PF, Zhang X, Thrasher JB, Li B. AAV-delivered short-hairpin RNA for androgen receptor gene silencing induces tumor eradication of prostate cancer xenografts in nude mice: A pre-clinical study. International Journal of Cancers. 2010, 126:764-774. (As corresponding author).
  • Li H, Ruan G, Li Z, Liu Z, Zheng X, Zheng H, Cheng G, Li B, Zhan M. The calcimimetic R-568 induces apoptotic cell death in prostate cancer cells. J Exp Clin Cancer Res. 2009 Jul 14; 28:100. PMCID: PMC2716307
  • Jun Yang, Jihong Liu and Li B. Beta2-microglobulin in prostate cancers. J Contemp. Urol Repro Oncol., 2009; 1(2):65-68. Review article in Chinese. (As corresponding author).
  • Yang J and Li B. HSP70 silencing combined with AIF. Editorial commentary on [Zhu et al. Heat shock protein 70 silencing enhances apoptosis inducing factor-mediated cell death in hepatocellular carcinoma HepG2 cells. Cancer Biol Ther. 2009; 8(9):792-798.] Cancer Biology and Therapy, 2009; 8(9):799-800. (As corresponding author).
  • Mohammad Saleem, Imtiyaz Murtaza, Rohinton Tarapore, Yewseok Suh, Vaqar Mustafa Adhami, Jeremy James Johnson, Imtiaz Ahmad Siddiqui, Naghma Khan, Mohammad Asim, Bilal Bin Hafeez, Li B, and Hasan Mukhtar. Lupeol Inhibits Proliferation of Human Prostate Cancer Cells by Targeting ß-catenin Signaling. Carcinogenesis, 2009; 30(5):808-817. PMCID: PMC2722146
  • Guodong Li, Dequan Wu and Li B. An update of autophagy study in human cancers. Chinese Journal of Cancer, 2009; 28(4):445-448. Review article in English & Chinese. (As corresponding author).
  • Li B and Zhang Da. Book review on [Clinical pathology of urological tumours. Editor, Mikuz G.]. J Urol., 2008; 180:2264.
  • Pi M, Chen L, Huang MZ, Zhu W, Ringhofer B, Luo J, Christenson L, Li B, Zhang J, Jackson PD, Faber P, Brunden KR, Harrington JJ, Quarles LD. GPRC6A null mice exhibit osteopenia, feminization and metabolic syndrome. PLoS ONE. 2008;3(12):e3858.
  • Yang J, Liu JH, Li B. [Association of mating type switching/sucrose non-fermenting (SWI/SNF) complex with prostate cancer].  National J Androl. 2008; 14(10):935-8.  Review article in Chinese. (As corresponding author).
  • Zhu Q, Tang J, Youn H, Tawfik O, Terranova PF, Du J, Raynal P, Thrasher JB, and Li B. Phosphoinositide 3-OH kinase p110b is essential for androgen receptor transactivation and tumor growth in prostate cancer. Oncogene, 2008; 27(33):4569-79. PMCID: PMC2597686 (As corresponding author).
  • Aijing Sun, Jianxi Tang, Yan Hong, Jiawu Song, Paul F. Terranova, J. Brantley Thrasher, Stan Svojanovsky, Hong-gang Wang and Li B. Androgen Receptor-dependent Regulation of Bcl-xL Expression: Implication in Prostate Cancer Progression. The Prostate, 2008, 68(4):453-461. (As corresponding author).
  • Shen FY, Tang JX and Li B. [An update on the role of PI3K signaling pathway in prostate cancer progression.] International J Urology & Nephrology, 2007; 27(3):130-133. Review article in Chinese. (As corresponding author).
  • Shen FY, Li B. [Anti-apoptotic effect of the androgen receptor in human prostate cancer]. National J Androl. 2007 Dec;13(12):1121-4. Review article in Chinese. (As corresponding author).
  • Guo QY and Li B. PI3K/AKT signaling inhibitors in prostate cancer treatment. International J Urology & Nephrology, 2007; 27(6):730-733. Review article in Chinese. (As corresponding author).
  • Li B. Editorial Comment on [Advanced but Not Localized Prostate Cancer is Associated With Increased Oxidative Stress ] Ofer Yossepowitcha, Ilya Pinchukc, Uri Gura, Avivit Neumannb, Dov Lichtenbergc and Jack Baniela. J Urol., 2007; 178:1238-1244.
  • Ilanchezhian Shanmugam, Guangming Cheng, Paul F. Terranova, J. Brantley Thrasher, Christie P. Thomas, and Li B. Serum/Glucocorticoid-induced Protein Kinase-1 Facilitates Androgen Receptor-dependent Cell Survival. Cell Death and Differentiation, 2007, 14(2):2085-2094. (As corresponding author).
  • Aijing Sun, Ilanchezian Shanmugam, Hyewon Youn, Jiawu Song, Paul F. Terranova, J. Brantley Thrasher, and Li B. Lithium suppress cell proliferation and E2F-mediated gene expression by disrupting E2F-DNA interaction in prostate cancer cells. The Prostate, 2007, 67(9):976-988. (As corresponding author).
  • Li B, Aijing Sun, Hyewon Youn, Yan Hong, Paul F. Terranova, J. Brantley Thrasher, and Pingyi Xu. Conditional Akt activation promotes androgen-independent progression of prostate cancer. Carcinogenesis, 2007, 28(3):572-83. (As corresponding author).
  • Li B, Liao XB, Fujito A, Thrasher JB, Shen F, Xu PY. Dual androgen-response elements mediate androgen regulation of mmp-2 gene expression in prostate cancer cells. Asian Journal of Andrology, 2007, 9(1):41-50. (As corresponding author).
  • Sun A, Tawfik O, Geyrad B, Thrasher JB, Hoesije, S, Li C and Li B. Aberrant expression of SWI/SNF catalytic subunits BRG1/BRM is associated with tumor development and increased invasiveness in prostate cancers. The Prostate, 2007; 67(2):203-13.  (As corresponding author).
  • Shen FY and Li B. Recent update on the era of Nano-based biosensor in prostatic specific antigen test. International J Urology & Nephrology, 2006; 26(5):230-233. Review article in Chinese. (As corresponding author).
  • Shen FY and Li B. Modern nanotechniques in molecular imaging and therapies of prostate cancer. International J Urology & Nephrology, 2006; 26(5):240-243. Review article in Chinese. (As corresponding author).
  • Song JW, Wang WD, You FY, Bian Z, Tang JX, Yao L, Li B. The development and reliability study fo high throughput assay for YMDD mutation by pyrosequencing. Chinese J. Med. Lab., 2005; 28(9)957-960.
  • Chen L, Meng S, Wang H, Bali P, Bai W, Li B, Atadja P, Bhalla KN, Wu J. Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824. Mol Cancer Ther. 2005; 4(9):1311-9.
  • Liao X, Tang S, Griebling T, Thrasher JB, and Li B. siRNA-mediated androgen receptor silencing leads to apoptotic cell death in prostate cancer. Mol Cancer Therapeutics, 2005, 4(4):505-15. (As corresponding author).
  • Liao X, Thrasher JB, Holzbeierlien J, Scott S, and Li B. GSK-3b activity is required for androgen-stimulated gene expression. Endocrinology, 2004, 145:2941-2949 (As corresponding author).
  • Liao X, Zhang L, Du J, Thrasher JB and Li B. GSK-3b suppression eliminates TRAIL resistance in prostate cancer. Mol Cancer Therapeutics, 2003; 2:1215-1222. (as corresponding author).
  • Liao X, Thrasher JB, Pelling J, Sang QX, Holzbeierlien J and Li B. Androgen stimulates MMP2 expression in human prostate cancer. Endocrinology 2003; 144:1656-1663. (as corresponding author).
  • Li B, Desai, S.A., MacCorkle-Chosnek, R.A., Fan, L. and Spencer, D.M. A novel conditional Akt 'survival switch' reversibly protects cells from apoptosis. Gene Ther 2002; 9(4):233-244.
  • Wu H, Yuan HR, Wu J, Wang J, Li B, Li P. Relationship of serum level of melatonin to age and prostate volume. J Guangdong Medical College, 2002; 20(5):343-344.
  • Li B and QP Dou. Bax degradation by the ubiquitin/proteasome pathway: involvement in tumor survival and progression. Proceedings of National Academy Society of USA. 2000; 97:3850-3855. PMCID: PMC18105
  • Dou QP and Li B. Proteasome inhibitors as potential anticancer agent. Drug Resistant Updates. 1999; 2:215-233.
  • Sun JZ, Nam S, Lee CS, Li B, et al. CEP1612, a dipeptidyl proteasome inhibitor, induces p21waf1 and p27kip1 expression and apoptosis and inhibits the growth of the human lung adenocarcinoma A-549 in nude mice. Cancer Research, 2000; 61:1280-1284.
  • Kanamaru H and Li B, et al. Immunohistochemical expression of p53 and bcl-2 proteins is not associated with sarcomatoid change in renal cell carcinoma. Urological Research. 1999; 27:169-173.
  • Li B, et al. Different expression of hepatocyte growth factor in papillary and nodular tumors of the bladder. International Journal of Urology. 1998; 5:436-440.
  • Tsuka H, Mori H and Li B, et al. Enhanced hepatocyte growth factor level in human prostate cancer treated with endocrine therapy. International Journal of Oncology. 1998; 13:169-176.

Meeting Abstracts (as the 1st author)

 

  1. Li B and Liao X.
    Androgen induction of MMP-2 expression in prostate cancer.
    September 2002; American Association for Cancer Research (AACR)
    Specific Conference on MMPs, Hilton Head Island, SC.
  2. Li B and Thrasher JB.
    GSK‑3b activity is required for androgen receptor transactivation in prostate cancer.
    April 2003. The American Urological Association (AUA), Annual Meeting, Chicago, IL.
  3. Liao X and Li B.
    siRNA-mediated AR silencing leads to apoptotic cell death in prostate cancer cells.
    March 2004, the American Association for Cancer Research (AACR) annual meeting. Orlando, FL
  4. Li B and Tang S.
    14-3-3 proteins in prostate cancer.
    Feb 2004, The first Gordon conference on [the Biology of 14-3-3]. Ventura, CA.
  5. Li B and Liao X.
    Bcl-xL as a downstream effecter in AR-mediated survival.
    October 2004, The 11th Annual Scientific Retreat, Prostate Cancer Foundation, Reno, NV
  6. Li B and Liao X.
    AR-mediated regulation of Bcl-xL expression in prostate cancer.
    Feb 2005, The Keystone Symposium of Hormonal Regulation of Tumorigenesis. Monterey, CA.
  7. Li B and Thrasher JB.
    Androgen Receptor-mediated Bcl-xL expression in prostate cancer.
    May 2005, The American Urological Association (AUA) annual meeting, San Antonio, TX.
  8. McIntosh J, Thrasher JB and Li B.
    Galpha12 is required for androgen-induced gene expression in prostate cancer.
    May 2006, the American Urological Association (AUA) annual Meeting, Atlanta, GA.
  9. Youn H, Thrasher JB  and Li B.
    G-proteins in modulation of AR transactivation.
    October 2006, The 85th Annual Meeting, South Central Section,
    American Urological Association (AUA), Santa Fe, NM
  10. Li B and Shanmugam I.
    SGK-1 facilitates AR-dependent survival in prostate cancer.
    November 2006, American Association for Cancer Research (AACR)
    Special Conference on “Inovations in Prostate Cancer Research”,
    San Francisco, CA
  11. Li B and Tang S.
    Androgen Receptor siRNA eliminates prostate cancer in vivo
    Mar 2007, “Molecular Targets for Cancer (X3)”, Keystone Symposium Series,
    Whistler Resort, Whistler, British Columbia, Canada
  12. Li B and Sun A.
    Systemic delivery of AAV-based AR siRNA constructs eradicates prostate cancer in nude mice.
    September 2007, DoD IMPaCT Retreat Meeting, Atlanta, GA
  13. Li B and Tang S.
    Conditional Akt activation promotes androgen-independent progression of prostate cancer.
    September 2007, DoD IMPaCT Retreat Meeting, Atlanta, GA
  14. Tang J, Hong Y, Thrasher JB and Li B.
    AAV-based AR siRNA constructs eradicate prostate cancer in nude mice.
    April 2008, American Association for Cancer Research (AACR) Annual Meeting, San Diego, CA
  15. Yang J, Tang J and Li B.
    GSK-3 modulates Autophagy after growth factor depletion.
    April 2008, American Association for Cancer Research (AACR) Annual Meeting, San Diego, CA
  16. Davis J, Thrasher JB and Li B.
    PI3K p110b is required for androgen receptor signaling and tumor progression in prostate cancers.
    May 2008, American Urological Association (AUA) Annual Meeting, Orlando, FL
  17. Benyi Li
    PI3K pathway in AR signaling and Prostate Cancer Progression
    August 2008, The 3rd IDeA Meeting, Washington D.C.,
  18. Benyi Li, Hyewon Youn, Qin Zhu, J. Brantley Thrasher.
    G-protein alpha-modulated PI3K p110beta activation is involved in androgen receptor transactivation in prostate cancers.
    April 2009, American Urological Association (AUA) Annual Meeting, Chicago, IL
  19. Yang J and Benyi Li
    GSK-3-modulated autophagy acts as a switch between necrosis and apoptosis
    April 2009, American Association for Cancer Research (AACR) Annual Meeting, Denver, CO.
  20. Yang J, Shenxue Xie, Cory Berkland and Benyi Li
    Nanoparticle-based delivery of androgen receptor siRNA for prostate cancer intervention.
    2011 IMPaCT Conference Poster Presentation
    Orlando, FL, March 10, 2011
  21. Yiling Huang, Laird Forrest and Benyi Li
    Targeted delivery of nanoparticle encapsulated p110beta specific inhibitor for prostate cancer intervention.
    2011 IMPaCT Conference Poster Presentation
    Orlando, FL, March 10, 2011
  22. Andrew James, Benyi Li, Jeffrey Holzbeierlein
    Natural compound alternol activates apoptosis and autophagy in prostate cancer cells.
    2011 AUA Annual Meeting,
    Washington DC, May 14-18, 2011.